Ledipasvir

Phase 3Small molecule

Johnson & Johnson

Ledipasvir is one of 77 small molecule programs targeting Hepatitis B Virus Infection. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatitis B Virus InfectionActive, not recruiting

Chronic HepatitisActive, not recruiting

Hepatitis CActive, not recruiting

Hepatitis B Virus InfectionPhase 2

Active, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

Hepatitis CPhase 3

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

Ledipasvir

Johnson & Johnson

Phase 3

2 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 5

Incivek

Vertex Pharmaceuticals

Preclinical

10 6

Intron a

Sanofi

Preclinical

7 7

Roferon-a

Roche

Preclinical

3 8

Dasabuvir

AbbVie

Preclinical

7 9

SOF/VEL

Gilead

Preclinical

4 10

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatitis C3 trials

Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa

Completed·AANRS, Emerging Infectious Diseases·Phase 2·NCT02405013·120 enrolled

Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C)

Completed·IInstituto de Investigación Marqués de Valdecilla·Phase 4·NCT02768961·64 enrolled

Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1

Completed·TTehran University of Medical Sciences·Phase 3·NCT02705534·50 enrolled

Chronic Hepatitis2 trials

A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT02421211·41 enrolled

Combination Therapy for Chronic Hepatitis C Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01805882·229 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions

Completed·VValme University Hospital··NCT02333292·1,128 enrolled

Chronic1 trial

Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC

Unknown status·NNational Hepatology & Tropical Medicine Research Institute·Phase 3·NCT02771405·150 enrolled

Hepatitis B Virus Infection1 trial

Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT03312023·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Ledipasvir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ledipasvir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ledipasvir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Ledipasvir

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatitis C3 trials

Chronic Hepatitis2 trials

Efficacy and Safety1 trial

Chronic1 trial

Hepatitis B Virus Infection1 trial

References

Drug Info

Quick Facts

Related News